Exploring clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine

Globally, more than 30% of the adult population has metabolic dysfunction-associated steatotic liver disease (MASLD). People with MASLD and more so with metabolic dysfunction-associated steatohepatitis (MASH) and MASLD-associated hepatic fibrosis can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and extrahepatic cancers.